Why IMI Matters to You

IMI will drive the creation of a vibrant and dynamic scientific environment and ensure a strong European biomedical science base. IMI matters specifically to you:

If you are a patient

• You may be directly involved in IMI through Patient Centred Projects, such as the development and validation of Quality of Life endpoints for your condition,
• Through the Education & Training pillar, IMI may provide patients with more information on their diseases as well as inform about the R&D process,
• IMI will improve access to innovative therapeutic approaches such as personalised medicine,
• IMI will provide a discussion forum on risk assessment of different therapeutic classes,
• IMI will provide a discussion forum on the R&D process,
• IMI will optimize clinical trail designs helping to accelerate access to new medicines, and
• IMI will increase collaboration with all relevant stakeholders.
  

If you are a Small and Medium-sized Enterprise (SME)

• Through development of and access to new and better drug safety and efficacy biomarkers IMI may reduce the risk of entering into clinical trials. This improved predictivity may also help attract venture capital companies and other investors who want to invest in early-stage innovation-based companies,
• IMI will foster an improved environment for discovering and developing new medicines using enabling technologies, diagnostics and potential therapies,
• IMI will provide a new source of R&D funding for financing technology development,
• IMI will facilitate access to databases and know-how normally unavailable to or prohibitively expensive for new biotech companies, increasing their chances of success, and
• IMI will increase collaboration with all relevant stakeholders.
  

If you are an academic

• IMI is a framework within which academia can compete for research projects in priority areas and establish collaborations with all stakeholders,
• IMI will provide early access to pre-competitive knowledge,
• IMI will deliver an improved research infrastructure with state-of-the-art technological equipment,
• IMI will increase mobility and knowledge sharing between the public and private sectors,
• IMI will increase co-ordination internationally on medical research topics,
• IMI will accelerate the application of research results, and
• IMI will increase collaboration with all relevant stakeholders.

If you are a regulator

• IMI will provide a discussion forum on risk assessment of different therapeutic classes with all stakeholders,
• IMI will deliver improved scientific information to support faster decision making in regulatory approvals,
• IMI will provide for earlier involvement of regulators in the R&D process,
• IMI will provide earlier access to pre-competitive knowledge,
• IMI will accelerate the application of new technologies to regulatory practices,
• IMI may reduce the risk of encountering post-marketing withdrawals while speeding access to new therapies, and
• IMI will increase collaboration with all relevant stakeholders.

If you are a Biopharmaceutical company

• IMI will enable faster drug discovery and development and help lower attrition rates,
• IMI will share the risk of implementing new technologies,
• IMI will provide greater access to pre-competitive knowledge,
• IMI may accelerate approvals through better collaboration with EMEA,
• IMI may reduce post-marketing withdrawals,
• IMI will optimize clinical trail designs,
• IMI will validate new assessment methods such as biomarkers,
• IMI will optimize the use of animals in safety evaluation,
• IMI will accelerate interpretation of safety findings through sharing pre-competitive toxicology data,
• IMI will develop more skilled professionals, and
• IMI will increase collaboration with all relevant stakeholders.

If you are in Member States, Associated States and Candidate Countries of the European Union

• IMI will support the creation of more R&D jobs in the EU,
• IMI will contribute to achieving the Lisbon objective for Europe to become the world’s strongest knowledge based economy and is a means of gaining global competitive advantage,
• IMI will contribute to the availability of more education and training in the biomedical arena,
• IMI will drive the creation of significant economic value through fostering small and large enterprises in Europe,
• IMI will enable more effective healthcare with its focus on translational science, and
• IMI will address the brain drain by strengthening the European science base helping countries retain and attract scientific talent.